Physician profile
Doris Yu
NPI 1972808996
$4,399.93
in general payments reported to CMS, 2019-2025
25 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $702 · 2022: $386 · 2023: $429 · 2024: $1,363 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221 · Education: $90.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.88 |
| Education | $90.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.81 | 2021-2025 | |
| Viiv Healthcare Company | $779.89 | 2024-2025 | Apretude |
| Horizon Therapeutics Plc | $344.33 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.99 | 2023-2024 | Xifaxan, Trulance |
| Opko Pharmaceuticals, LLC | $276.04 | 2021-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals Lp | $255.53 | 2024-2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.13 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $178.33 | 2024-2025 | Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $158.96 | 2023-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Lilly USA, LLC | $142.48 | 2025 | Zepbound, Mounjaro, Jardiance |
| Lundbeck LLC | $132.16 | 2024-2025 | Rexulti |
| Biogen, INC. | $109.48 | 2021-2022 | |
| Abbott Laboratories | $104.33 | 2024-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $86.72 | 2025 | |
| Shield Therapeutics INC | $74.95 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $57.47 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.03 | 2021 | |
| Genentech USA, INC. | $45.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $32.23 | 2021 | |
| Merck Sharp & Dohme LLC | $21.88 | 2022 | |
| Vivus LLC | $21.81 | 2023 | Pancreaze |
| Amgen INC. | $20.99 | 2022 | |
| Esperion Therapeutics, INC. | $20.85 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.66 | 2025 | |
| Phadia US INC. | $15.80 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.